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Abstract
Background: Tumor necrosis factor alpha (TNF-α) is deeply related to pathogenesis of neurodevelopmental
disorders, especially depression. The aim of this study was to explore potential relationships between sera TNF-α
levels and mood and anxiety disorders in systemic lupus erythematosus (SLE) patients.
Methods: We included 153 consecutive SLE patients (women 148; median age 30; range 10–62) and 40 (women
37; mean age 28.5; range 12–59) age- and sex-matched healthy controls. Mood and anxiety disorders were
determined through Beck Depression and Beck Anxiety Inventory. SLE patients were further assessed for clinical and
laboratory SLE manifestations. TNF-α levels were measured by enzyme-linked immunosorbent assay using
commercial kits.
Results: Depressive symptoms were identified in 70 (45.7 %) SLE patients and in 10 (25 %) healthy controls (p < 0.001).
Anxiety symptoms were identified in 93 (60.7 %) SLE patients and in 16 controls (40 %) (p < 0.001). Sera TNF-α levels
were increased in SLE patients with depressive symptoms (p < 0.001) and with anxiety symptoms (p = 0.014). A direct
correlation between the severity of depressive symptoms and sera TNF-α levels (r = 0.22; p = 0.003) was observed. TNF-
α levels were significantly increased in patients with active disease (p = 0.012). In addition, we observed a correlation
between sera TNF-α levels and disease activity (r = 0.28; p = 0.008). In the multivariate analysis, sera TNF-α levels were
independently associated with depressive symptoms (t = 3.28; 95 % CI 1.08–2.2; p = 0.002).
Conclusions: Sera TNF-α levels are increased in SLE patients with mood and anxiety disorders. In SLE, sera TNF-α levels
are independently associated with mood disorders. The etiology of mood disorders is still debated in SLE, but our
findings suggest the presence of immunological basis for depression in SLE.
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Background
Systemic lupus erythematosus (SLE) is a chronic, inflam-
matory, immune-mediated disease with diverse clinical
manifestations, affecting 0.1 % of the general population
[1]. A large fraction of SLE patients demonstrate organic
psychiatric and neurological disorders, indicating central
nervous system (CNS) involvement [2]. Neuropsychiatric
(NP) manifestations in SLE are diverse and may include
major manifestations (i.e., stroke syndromes, severe or-
ganic brain syndrome, seizures, psychotic episodes, etc.)
and minor abnormalities, including mood disorders and
less severe cognitive deficits [2]. While the survival of
SLE patients has increased substantially, such improve-
ment, however, transforms into more damage accrual
and disability that adversely affect the psychosocial
health of SLE patients [3].
Depression and anxiety are commonly encountered
in SLE patients [4, 5]. Some studies have found that
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greater disease activity, SLE severity, or longer disease
duration increases vulnerability for clinical depression
in SLE [4, 6–8]. Others have focused on physical dis-
ability and stress of living with a chronic disease as
cause of depression in SLE [4, 5, 9, 10]. Although the
majority of studies have focused on depressed mood
or clinical unipolar depression in SLE, some authors
suggest that symptoms of anxiety may be equally im-
portant in this cohort [8, 10, 11].
The pathogenesis of mood and anxiety disorder in SLE
remains unclear. To date, studies aiming to investigate
the relationship between mood disorders, anxiety, and
proinflammatory cytokines have been scarce [12–15]. In
the last two decades, since the initial reports of neural-
immune interactions in depression, studies have shown
a clear association between activation of the immune
system, peripheral proinflammatory cytokines, and psy-
chiatric symptoms [12]. The tumor necrosis factor alpha
(TNF-α) is a pleiotropic cytokine that produces different
stimuli in various physiological and pathological condi-
tions [16]. TNF-α exerts its biological effect mainly by
binding to tumor necrosis factor receptor 1 (TNFR1)
and receptor 2 (TNFR2), causing activation of complex
signaling cascades that mediate different intracellular ef-
fects. In the brain, TNFR1 seems to show a constitutive
pattern of expression whereas TNFR2 is mainly
expressed under stimulatory conditions [17]. TNF-α may
underlie the mechanism of depression by an activation
of the hypothalamo-pituitary-adrenocortical (HPA) axis,
an activation of neuronal serotonin transporters and the
stimulation of the indoleamine 2,3-dioxygenase which
leads to tryptophan depletion [18].
Studies link peripheral cytokines and pathogenesis of
depression in Alzheimer’s disease [17], in atypical de-
pression [19], in major depressive disorder [19–21], and
in multiple sclerosis [22, 23]. The aim of this study was
to explore potential relationships between sera TNF-α
levels and mood and anxiety disorders in SLE patients.
Methods
Design and subjects
Consecutive SLE patients followed at the Rheumatology
Outpatient Clinic of State University of Campinas, be-
tween January 2010 and December 2011, were invited to
participate in this cross-sectional study. Patients were in-
cluded in the present study if they (i) fulfilled at least
four criteria of American College of Rheumatology
(ACR) [24] and (ii) had a follow-up duration of at least
6 months. Patients taking psychotropic medication were
excluded from the study.
Healthy volunteers were included as a control group.
The healthy controls were matched for age, sex, and
demographic background. They were recruited from
local community. Additionally, those control subjects
who had histories of a psychiatric disorder other than
depression diagnosed by a medical practitioner, or have
been taking psychotropic medications, were also
excluded.
Ethics statement
This study was approved by the ethics committee at our
institution (Faculty of Medical Sciences, State University
of Campinas), and informed written consent was ob-
tained from each participant and/or legal guardian.
Clinical features
All patients had their medical histories and clinical and
serological characteristics evaluated at study entry ac-
cording to the ACR [24]. Features included in this proto-
col, such as age at onset of disease (defined as the age at
which the first symptoms clearly attributable to SLE oc-
curred), age at diagnosis (defined as the age when pa-
tients fulfilled four or more of the 1982 revised criteria
for the classification of SLE) [24], and follow-up time
were taken from medical charts. All clinical manifesta-
tions and laboratory findings were recorded at the day of
blood withdrawal. Nephritis was diagnosed on the basis
of proteinuria exceeding 0.5 g/L with abnormal urinary
sediment and/or histological findings. Nephrotic syn-
drome was defined as proteinuria in excess of 3.0 g/day.
Hematological alterations were ascribed to lupus only
in the absence of bone marrow suppression (leukopenia
<4000 cells/mm3, thrombocytopenia <100,000 cells/
mm3, hemolytic anemia). We also analyzed the presence
of malar rash, discoid lesions, subacute cutaneous le-
sions, cutaneous vasculitis, photosensitivity, oral ulcers,
arthritis, and serositis. Neurological and psychiatric in-
volvement was defined according to ACR [25].
Treatment prescribed at the time of blood withdrawal,
as well as its adverse events related to drug use, was re-
corded. Doses of oral and parenteral corticosteroids were
analyzed and converted to the equivalent doses of
prednisone.
Laboratory features
Antinuclear antibodies (ANA) were determined by indir-
ect immunoflurescence using HEp-2 cells as substrate
and regarded as positive if higher than 1:40. Antidouble
stranded DNA (dsDNA) antibodies were determined by
indirect immunofluorescence using Crithidia as sub-
strate and considered positive if higher than 1:10. Pre-
cipitating antibodies to extractable nuclear antigens
(ENA) including Ro (SSA), La (SSB), and Sm were de-
tected by a standardized enzyme-linked immunosorbent
assay (ELISA) method and considered positive if higher
than 1:40. Rheumatoid factor was detected by nephelom-
etry and regarded as positive if higher than 10. Anticar-
diolipin antibodies (aCL) of the IgG and IgM isotypes
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were measured by an ELISA method [26]. The lupus
anticoagulant (LA) activity was detected by coagulation
assays in platelet-free plasma obtained by double centri-
fugation, following the recommendation of the subcom-
mittee on LA of the Scientific and Standardization
Committee of the International Society of Thrombosis
and Homeostasis [27]. These measurements were carried
out twice, at an interval of 12 weeks.
Disease activity/cumulative damage evaluation
SLE patients were assessed for disease activity and cu-
mulative damage. Disease activity was measured by the
Systemic Lupus Erythematosus Disease Activity Index
(SLEDAI) [28]. SLEDAI scores range between 0 and 105.
Score of ≥3 was considered active disease [29]. Cumula-
tive SLE-related damage in all patients was determined
using the Systemic Lupus International Collaborating
Clinics (SLICC)/ACR Damage Index (SDI) at the time of
blood withdrawal. The range of SDI score varies from 0
to 47 [30].
Blood samples
Nine milliliters of peripheral blood were drawn through
venipuncture of the antecubital veins in all subjects.
Serum was obtained by centrifugation (3000 rpm for
15 min), and separated sera were kept in aliquots at
−80 °C until the time of assay. None of the samples were
taken during an episode of acute or chronic infection be-
cause TNF-α could be increased due to a secondary
cause [31]. Commercially available kits from R&D Sys-
tems (London, UK) were used for the measurement of
sera TNF-α levels by ELISA, carried out in accordance
with the manufacturer’s instructions.
Mood and anxiety evaluation
To assess clinically symptoms of depression and anx-
iety, the Beck Depression Inventory (BDI) [32, 33]
and Beck Anxiety Inventory (BAI) [34, 35] were used.
Validated Brazilian Portuguese version of BDI and
BAI was applied [33, 35]. All the participants an-
swered both inventories. These scales consist of 21
items, each describing a common symptom of depres-
sion/anxiety. The respondent is asked to rate how
much he or she has been bothered by each symptom
over the past month on a 4-point scale ranging from
0 to 3. The items are summed to obtain a total score
that can range from 0 to 63. The cutoffs used for the
BDI are 0–13, no/minimal depression; 14–19, mild
depression; 20–28, moderate depression; and 29–63,
severe depression and for the BAI are 0–7, no/min-
imal level of anxiety; 8–15, mild anxiety; 16–25, mod-
erate anxiety; and 26–63, severe anxiety.
Statistical analysis
We performed normality tests. Our data did display a
non-parametric distribution in the Shapiro-Wilk test;
thus, we used the Mann-Whitney U test for comparison
of TNF-α and independent groups (i.e., groups (SLE
patients/controls), disease activity (SLEDAI ≥ 3/SLEDAI
< 3), cumulative damage (SDI ≥ 1/SDI = 0), sex (male/fe-
male), and medication (taking any medication/without
medication). The correlations between depressive/anx-
iety symptoms and TNF-α were explored by Spearman’s
rank correlation. Multivariate analysis was performed in-
cluding age, SLE duration, disease activity, and cumula-
tive damage, severity of depression, and anxiety. TNF-α
was used as a dependent variable. The level of signifi-
cance was set to p < 0.05. Statistical analysis was per-
formed using SPSS® 21.0.
Results
Demographics and clinical features
We included 153 consecutive SLE patients. One hun-
dred forty-eight (96.73 %) were female with median age
of 30 years (range 10–62). The median of disease dur-
ation was 9 years (range 0–33 years). The control group
consisted of 40 healthy controls (37 women) with a me-
dian age of 28.5 years (range 12–59 years). Patients and
healthy controls were statistically comparable in terms
of age and sex (Table 1).
At the time of study entry, 68 (44.4 %) SLE patients had
active disease (SLEDAI ≥3) with median SLEDAI scores of
8 (range 2–18). The 85 (55.6 %) inactive patients had a
median SLEDAI score of 0 (range 0–2). At the same time,
77 (50.32 %) SLE patients had cumulative damage (SDI
>1) and median SDI scores of 1 (range 0–9).
Depressive symptoms were identified in 70 (45.7 %) SLE
patients and in 10 (25 %) healthy controls (p < 0.001). The
mean of BDI scores in SLE patients was 15.08 ± 13.02
(range 0–62) and 4.68 ± 4.27 (range 0–16) in controls.
The mean of BAI scores was 15.92 ± 15.25 (range 0–63) in
Table 1 Demographic and clinical features of SLE patients and
healthy controls at study entry
SLE patients
N = 153 (%)
Healthy controls
N = 40 (%)
Sex
Female 148 (96.7) 37 (92.5)
Age (years) 30 (range 10–62) 28.5 (range 12–59)
Disease duration (years) 9 (range 0–33) –
SLEDAI score
SLEDAI ≥3 N = 68 8 (range 4–18) –
SLEDAI <3 N = 85 0 (range 0–2)
SDI ≥1 N = 77 1 (range 0–9) –
Results were given as median and range
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SLE patients and 6.88 ± 5.84 (range 0–21) in controls.
Anxiety symptoms were observed in 93 (60.7 %) in
SLE patients and in 16 (40 %) controls (p < 0.001).
The extent of depressive and anxiety symptoms is de-
scribed in Table 2.We did not observe an association
between disease activity and depression (p = 0.22) or
anxiety (p = 0.88).
Cytokine assay
The median of TNF-α levels was 1.93 pg/mL (range
0.45–11.17) in SLE patients compared to 1.50 pg/mL
(range 0.39–6.35) in healthy controls (p = 0.003). The
median of TNF-α levels in SLE patients with depressive
symptoms was 2.42 (range 0.45–11.17) versus 1.45
(range 0.57–3.23) in SLE patients without depressive
symptoms (p < 0.001). The median in SLE patients with
anxiety symptoms was 2.15 (range 0.45–11.17) versus
1.59 (0.7–3.23) in SLE patients without anxiety
symptoms (p = 0.014). A direct correlation between sera
TNF-α levels and the severity of depression symptoms
(r = 0.51; p < 0.001) was observed. All Spearman rank
correlation analyses between TNF-α and other variables
are described in Table 3.
TNF-α levels were further significantly increased in
patients with active disease (p = 0.012). In addition,
we observed a correlation between sera TNF-α levels
and disease activity (r = 0.28; p = 0.008). No associ-
ation between TNF-α levels and other clinical, labora-
tory variable, SDI scores, and current medication was
observed. No difference in TNF-α levels was observed
between patients with and without hydroxychloro-
quine or other immunosuppressants. In the multivari-
ate analysis, sera TNF-α levels were independently
associated with depressive symptoms (t = 3.28; 95 %
CI 1.08–2.2; p = 0.002).
Discussion
Substantial evidences implicate inflammation as a critical
mediator in the pathophysiology of mood and anxiety
disorders. Peripheral cytokines produced during the
inflammatory response may be useful biomarkers when
investigating the potential relationship between inflam-
mation and mood and anxiety disorders [36]. We aimed
to explore potential relationships between sera TNF-α
levels and mood and anxiety disorders in SLE patients.
There are animal models and human studies that link
peripheral cytokine and inflammatory responses signal
in the brain [37–43]. Several studies have investigated
the role of inflammation in depression [43–45]. Animal
studies have shown that injection of proinflammatory
cytokines in rodents result in a sickness behavior, includ-
ing decreased social exploration, decreased appetite, and
decreased activities [44].
Depression and sickness behavior may be the result
of many physiological stressors in life [44]. We ob-
served a direct correlation between sera TNF-α levels
and the severity of depression symptoms. Sickness be-
havior has been proved to be mediated by proinflam-
matory cytokines, such as interleukin (IL)-1 and IL-6
and TNF-α [46]. These inflammatory cytokines inter-
act with practically every pathophysiologic domain
relevant to depression, including neurotransmitter
metabolism, neuroendocrine function, and synaptic
plasticity [19].
There are, at least, more three mechanisms that link
the activation of the cytokine system, of which TNF-α is
a part, to the pathophysiology of depression [18]. First,
the activation of the cytokine system might play a causa-
tive role in the depression-related activation of the HPA
axis [14, 47, 48]. The stress response system is intricately
linked with proinflammatory signaling. The release of
TNF-α and interleukin 6 have been shown to increase
the levels of corticotropin-releasing hormone (CRH), ad-
renocorticotropic hormone (ACTH), and cortisol which
act directly on hypothalamic and pituitary cells [49–53].
The upregulation of the HPA axis is an important find-
ing associated with depression [54, 55], highlighting the
potential for direct clinical significance of raised proin-
flammatory cytokines, mainly TNF-α [12].
Second, TNF-α activates neuronal serotonin trans-
porters [43, 47]. During the process of depression, the
uptake of serotonin is diminished. Drugs like selective
serotonin reuptake inhibitors (SSRI) are used in the ther-
apy of depression because SSRIs lead to recovery from
depression via deactivation of serotonin transporters
[47]. One study demonstrated that TNF-α stimulated
serotonin uptake in both a rat embryonic raphe cell line
and in mouse midbrain and striatal synaptosomes. These
results provided evidence that TNF-α can acutely regu-
late neuronal serotonin transporter activity [43].
Table 2 Percentage of all individuals included in the study, according the severity of depression and anxiety symptoms
Severity Depression SLE patients (%) Depression controls (%) Anxiety SLE patients (%) Anxiety controls (%)
Mild 23 (32.8) 10 (24.4) 29 (31.2) 11 (64.7)
Moderate 19 (27.1) 0 37 (39.8) 5 (29.4)
Severe 28 (40) 0 29 (31.2) 0
Total 70 (45.7) 10 (25) 93 (60.7) 16 (40)
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Third, TNF-α stimulates indoleamine 2,3-dioxygenase
(IDO) leading to tryptophan depletion. The activation of
IDO by TNF-α additionally leads to the production of
glutamatergic agonists. The role of increased glutamater-
gic neurotransmission in the pathogenesis of depression
remains inconclusive [56, 57]. The higher consumption
of serotonin and its precursor tryptophan due to IDO
activation may justify the reduced availability of sero-
tonin and link TNF-α to depression [14, 47].
In addition, the relation between TNF-α and depression
in SLE patients may be explained by the long-term use of
corticosteroids. The hypothesis of depression as a stress-
related disorder is that chronic stress derived from long-
term use of corticosteroids impairs corticosteroid receptor
signaling [58]. Corticotrophin-releasing hormone and ar-
ginine vasopressin are the main drivers of the stress hor-
mone system that elicit corticotrophin into the periphery
and thereby activate the corticosteroid release from the
adrenal cortex [58]. A severe clinical condition and an in-
adequate adaptation to stress can appear when these stress
hormones are persistently hypersecreted [58]. There was
no association between corticosteroids and TNF-α in our
cohort. In fact, we did not evaluate long-term use of corti-
costeroids; we just evaluated current medication dosage.
Patients with autoimmune disease have higher levels of
proinflammatory cytokines [59–61]; consequently, they
have a more expressive interaction. Although these in-
flammatory theory of depression have been studied in de-
pression in Alzheimer’s disease [17], in atypical depression
[19], in major depressive disorder [19–21], and in multiple
sclerosis [22, 23], these mechanisms have not been eluci-
dated in SLE so far.
In this study, we observed higher sera levels of TNF-α
in individuals with depression and with anxiety. We ob-
served that sera TNF-α levels in SLE patients were posi-
tively correlated with the severity of depression. Another
cross-sectional study supports our finding. The data
included 54 SLE patients and 54 healthy controls, and
higher sera TNF-α was associated with more severe
depressive symptoms [59]. These findings suggest a po-
tential role of TNF-α on depressive symptoms in SLE
patients.
Our data shows higher prevalence of depression and
anxiety in SLE patients compared to healthy controls.
High prevalence of mood and anxiety disorders in SLE pa-
tients is in accordance with estimates reported in previous
studies [3, 6, 62, 63]. Comparative studies of depression
and anxiety between SLE and other disorders are limited
by their relatively small sample sizes, comparison with
relatively rare inflammatory diseases and the lack of
matched healthy controls with background prevalence of
depression and anxiety for comparison [64–66].
Given the elevated rates of depressive and anxiety dis-
orders observed in SLE patients, it is important to con-
sider some crucial factors. Disease activity and severity
in SLE may contribute to psychiatric symptomatology
through shared pathophysiological mechanisms, includ-
ing antineuronal and antiphospholipid antibodies [67],
and proinflammatory cytokines [68]. In addition, disease
duration and CNS complications may increase vulner-
ability for psychiatric disorders in SLE patients [6].
We observed that TNF-α levels were significantly in-
creased in patients with active disease. Previous studies
reported an association between this cytokine and dis-
ease activity [60, 69–72], suggesting that TNF-α could
be a potential biomarker to predict flares in SLE pa-
tients. However, in our cohort, we did not observe an as-
sociation between disease activity and depression/
anxiety. Our data corroborates previous studies that did
not observe an association between depressive and anx-
iety disorders and disease activity in SLE patients [4, 7].
Previous studies have associated symptoms of depression
and anxiety with physical disability and stress of living
with a chronic disease [5]. Psychological distress may be
associated with SLE outcomes, including fatigue [73],
physical disability [74], and decreased cognitive func-
tioning [75]. Mood disorder and anxiety might be sec-
ondary to SLE activity or to psychological distress [4].
Longitudinal studies are necessary to determine the pos-
sible role of each component in relation to cause-effect.
It is important to consider some limitations of the
study analyzing depression mediated by TNF-α, such as
the small number of healthy controls included and the
short follow-up period. Longitudinal studies are neces-
sary to determine the causal relationship between TNF-
α and depression in SLE patients.
Conclusions
In summary, sera TNF-α levels are increased in SLE pa-
tients with mood and anxiety disorders. In SLE, sera
TNF-α levels were independently associated with
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depression and with disease activity. The etiology of
mood disorders is still debated in SLE, but our findings
suggest the presence of immunological basis for depres-
sion in SLE patients.
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